A Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety Between Administration of BR2021 and BR2021-1
The purpose of this clinical study is to compare and evaluate the pharmacokinetic characteristics and the safety between administration of BR2021 and BR2021-1 in patients with metastatic adenocarcinoma of the pancreas
Metastatic Adenocarcinoma of the Pancreas
DRUG: BR2021|DRUG: BR2021-1
AUCt, Area under the Plasma Concentration-Time Curve from 0 to time t, 0~72 hours after administration|Cmax, Maximum Concentration of Drug in Plasma, 0~72 hours after administration
The purpose of this clinical study is to compare and evaluate the pharmacokinetic characteristics and the safety between administration of BR2021 and BR2021-1 in patients with metastatic adenocarcinoma of the pancreas